74 Chapter 3 13. Collij LE, Konijnenberg E, Reimand J, Kate MT, Braber AD, Alves IL, et al. Assessing Amyloid Pathology in Cognitively Normal Subjects Using (18)F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019;60(4):541-7. 14. Golla SS, Verfaillie SC, Boellaard R, Adriaanse SM, Zwan MD, Schuit RC, et al. Quantification of [(18)F]florbetapir: A test-retest tracer kinetic modelling study. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2019;39(11):2172-80. 15. van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2013;54(9):1570-6. 16. Lammertsma AA. Forward to the Past: The Case for Quantitative PET Imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017;58(7):1019-24. 17. Verfaillie SCJ, Golla SSV, Timmers T, Tuncel H, van der Weijden CWJ, Schober P, et al. Repeatability of parametric methods for [18F]florbetapir imaging in Alzheimer’s disease and healthy controls: A test–retest study. Journal of Cerebral Blood Flow & Metabolism. 2020:0271678X20915403. 18. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer’s disease and cognitively normal subjects. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2012;53(3):378-84. 19. Chiotis K, Saint-Aubert L, Boccardi M, Gietl A, Picco A, Varrone A, et al. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiology of aging. 2017;52:214-27. 20. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloidbeta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2013;54(1):70-7. 21. Joshi AD, Pontecorvo MJ, Lu M, Skovronsky DM, Mintun MA, Devous MD, Sr. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015;56(11):1736-41. 22. Camus V, Payoux P, Barre L, Desgranges B, Voisin T, Tauber C, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. European journal of nuclear medicine and molecular imaging. 2012;39(4):621-31. 23. Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Archives of neurology. 2011;68(11):1404-11.
RkJQdWJsaXNoZXIy MjY0ODMw